Debt-free Balance SheetZero reported debt materially reduces financing cost risk and preserves strategic optionality for a cash-burning R&D company. Over the next 2–6 months this structural strength makes it easier to negotiate non-debt funding or partner deals without imminent covenant pressure.

Distinct Nanoparticle Pipeline (SpagoPix, Tumorad)A focused pipeline on nanoparticle-based MRI contrast and theranostic approaches is a durable competitive asset. These differentiated modalities target diagnostic clarity and targeted imaging/therapy, increasing long-term partnership and licensing appeal to larger pharma and imaging players.

Narrowing Net Losses 2023–2025A sustained reduction in net loss over multiple years signals improving cost control or operational efficiency. If maintained, this trend extends runway and reduces future financing needs, improving the likelihood of reaching clinical inflection points or partner-readiness.

Bears Say

Persistent Operating Cash BurnConsistent negative operating cash flow shows the business remains cash-consuming and reliant on external financing. Over months this creates dilution risk or project delays if capital markets tighten, constraining the firm's ability to autonomously fund clinical development milestones.

Sharp, Volatile Revenue DeclineA severe one-year revenue drop and historically small, unstable top line undermine durable commercial traction. For a biotech aiming for partnerships, unreliable revenue complicates budgeting and reduces negotiating leverage, potentially slowing development or commercialization timelines.

Erosion Of Equity And Deeply Negative ROEMaterial declines in equity and persistently negative ROE indicate ongoing shareholder value erosion. Structurally, this signals the company has not yet converted R&D investment into value, increasing the likelihood of future equity raises and long-term dilution risk for existing shareholders.

SPAGO FAQ

What was Spago Nanomedical AB’s price range in the past 12 months?

Spago Nanomedical AB lowest stock price was kr0.06 and its highest was kr0.33 in the past 12 months.

What is Spago Nanomedical AB’s market cap?

Spago Nanomedical AB’s market cap is kr77.07M.

When is Spago Nanomedical AB’s upcoming earnings report date?

Spago Nanomedical AB’s upcoming earnings report date is May 07, 2026 which is in 55 days.

How were Spago Nanomedical AB’s earnings last quarter?

Currently, no data Available

Is Spago Nanomedical AB overvalued?

According to Wall Street analysts Spago Nanomedical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Spago Nanomedical AB pay dividends?

Spago Nanomedical AB does not currently pay dividends.

What is Spago Nanomedical AB’s EPS estimate?

Spago Nanomedical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Spago Nanomedical AB have?

Spago Nanomedical AB has 661,572,800 shares outstanding.

What happened to Spago Nanomedical AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Spago Nanomedical AB?

Currently, no hedge funds are holding shares in SE:SPAGO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Spago Nanomedical AB

Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.